Why Amylyx is pulling ALS drug Relyvrio from US market after study
Time:2024-05-21 07:02:48 Source:opinionsViews(143)
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
You may also like
- Siblings trying to make US water polo teams for Paris Olympics
- China Enhances Judicial Protection for Minors Against Sexual Violations
- Vocational Education Turns Youngsters into World Champions
- Spring Bud Girls Receive Gifts ahead of Int'l Children's Day
- Lynn Williams breaks NWSL goal
- Hexi District Offers Convenient Reading Service to Readers in N China's Tianjin
- Across China: Slow Train Provides Mobile Library Along Yangtze River
- Economic Watch: Beijing Sees Booming Holiday Consumption
- College baseball notebook: Conference tournaments to decide NCAA automatic bids and many at